Abstract 1,25-Dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ], the most active metabolite of vitamin D 3 , has significant antitumor activity in a broad range of preclinical models of cancer. In this study, we show that the Iroquois homeobox gene 5 (Irx5) is down-regulated by 1,25(OH) 2 D 3 in human prostate cancer samples from patients randomly assigned to receive weekly high-dose 1,25(OH) 2 D 3 or placebo before radical prostatectomy. Down-regulation of Irx5 by 1,25(OH) 2 D 3 was also shown in the human androgen-sensitive prostate cancer cell line LNCaP and in estrogen-sensitive MCF-7 breast cancer cells. Knockdown of Irx5 by RNA interference showed a significant reduction in LNCaP cell viability, which was accompanied by an increase in p21 protein expression, G 2 -M arrest, and an increase in apoptosis. The induced apoptosis was partially mediated by p53, and p53 protein expression was increased as a result of Irx5 knockdown. Cell survival was similarly reduced by Irx5 knockdown in the colon cancer cell line HCT 116 and in MCF-7 breast cancer cells, each being derived from clinical tumor types that seem to be inhibited by 1,25(OH) 2 D 3 . Overexpression of Irx5 led to a reduction of p21and p53 expression. This is the first report that Irx5 is regulated by1,25(OH) 2 D 3 in humans and the first report to show that Irx5 is involved in the regulation of both the cell cycle and apoptosis in human prostate cancer cells. Irx5 may be a promising new therapeutic target in cancer treatment.
1,25-Dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) promises to be effective in the treatment and prevention of cancer. Numerous in vitro and in vivo studies have shown the ability of biologically active analogues of vitamin D to potently inhibit the proliferation of many different cell types, including carcinomas of the prostate, breast, colon, skin, brain, and myeloid leukemia cells (1, 2) . 1,25(OH) 2 D 3 has also been shown to induce apoptosis in several tumor models (3 -8) and to inhibit angiogenesis and tumor invasion (9 -14) . However, the molecular factors that mediate these processes have yet to be clearly defined.
Members of the Iroquois gene family play multiple roles in patterning and regionalization of embryonic tissues during development and are highly conserved from Drosophila to mammals (15 -21) . The Iroquois homeobox (Irx) genes were first identified in Drosophila because of their role in the control of proneural gene expression (16, 22) . In Drosophila, the Iroquois gene cluster consists of three Irx genes, whereas in mammals, six genes exist in two clusters. The mammalian IrxA cluster (Irx1, Irx5, and Irx4) is located on chromosome 8, whereas the IrxB cluster (Irx3, Irx2, and Irx6) is found on chromosome 16 . Iroquois protein products bind DNA, at least in part through their homeodomain motif, a highly conserved 63 -amino acid sequence, and seem to act as both transcriptional activators and repressors (23 -25) . Outside the homeodomain, Irx family members share little sequence similarity, but all Irx transcription factors have a conserved motif called the Iro box.
Homeobox genes are developmental regulators that are essential for growth and differentiation, including early embryonic patterning, cell-type specification, and organogenesis. Increasing evidence indicate that normal development and tumorigenesis are intimately related, and the anomalous expression of many homeobox genes has been detected in a number of cancers, including prostate (26 -29) . Evidence that homeobox genes are involved in the regulation of proliferation through their interaction with several cell cycle regulators, including p21, p27, and cyclin D1, is accumulating (30) . Recent data also suggest that homeobox genes play a role in regulating apoptosis, angiogenesis, and/or metastasis; however, very little is known about the specific signaling pathways involved (31, 32) . A number of homeobox genes have been shown to be regulated by vitamin D (33) .
Materials and Methods
Chemicals. 1,25(OH) 2 D 3 was a kind gift from Dr. Milan Uskokovic, Hoffmann-La Roche. A 50 -3 mol/L stock solution dissolved in absolute ethanol was stored at -80jC and protected from light.
Patients. The eligibility criteria and procedures of our randomized trial of high-dose 1,25(OH) 2 D 3 or placebo before prostatectomy have been previously described (34) . Briefly, 44 patients were randomly assigned to receive 1,25(OH) 2 D 3 (0.5 Ag/kg) or identical placebo weekly for 4 wk before prostatectomy. Prostatectomy was carried out 4 F 1 d after the last dose of 1,25(OH) 2 D 3 . Whereas the primary goal of the study was the interrogation of prostate cancer tissue for a series of biomarkers using immunohistochemistry in fixed specimens, snapfrozen tumor samples were obtained from a subset of patients for the purpose of exploratory studies of the effect of high-dose 1,25(OH) 2 D 3 on gene expression at the RNA level. After surgical removal, prostate tissues were embedded in Cryomatrix (Thermo Shandon), snap frozen in a solution of liquid pentane and dry ice, and stored at -80jC.
Cell lines. LNCaP and MCF-7 cells were obtained from American Tissue Culture Collection. Cells were subcultured every 48 to 72 h in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). Cells were incubated at 37jC with standard 5% CO 2 content in a humidified incubator. HCT 116 cells were a kind gift from Dr. Bert Vogelstein (Johns Hopkins University). HCT 116 cells were cultured in McCoy's 5A medium (Invitrogen) with 10% fetal bovine serum. The LNCaP p53 dominant-negative pC53Trp248 cells (248 mutant) and the control pRC-CMV were generously provided by Dr. Mark Garzotto (Portland VA Medical Center). The pC53Trp248 plasmid contains a mutant form of p53, which has a Trp substitution at the 248 position that allows it to inactivate wild-type p53. LNCaP cells stably transfected with the pC53Trp248 plasmid (LNCaP/p53DN) markedly overexpress dominant-negative p53 by immunoblot analysis compared with control (pRC-CMV) -transfected cells. Results from a transient transfection of LNCaP/p53DN cells with a p21 promoter-luciferase reporter plasmid showed that overexpression of the 248-p53 mutant inactivates the function of wild-type p53 in LNCaP cells (data not shown).
RNA extraction from human tumors. Snap-frozen human prostatectomy specimens containing z90% cancer (determined by histology analysis by a clinical pathologist) were pulverized by mortar and pestle in liquid nitrogen and homogenized in TRIzol reagent with a Tissue Tearor Homogenizer. RNA was extracted from the homogenized tissues according to the manufacturer's instructions (Life Technologies, Bethesda Research Laboratories).
Oligonucleotide microarrays. Labeled cRNA was prepared from 10 RNA samples: five individual cases [1,25(OH) 2 D 3 treatment] and five individual placebo controls. Each sample target was hybridized to an HG-U133A Human GeneChip array (22,283 transcripts; Affymetrix). All quality control tests indicated good sample performance. Gene expression profiling was done in the Affymetrix Microarray Core of the Gene Microarray Shared Resource at Oregon Health and Science University.
RNA extraction from cell lines. LNCaP cells grown in 60-mm plates were washed with PBS and subsequently lysed in RSB lysis buffer [10 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1.5 mmol/L MgCl, 0.65% NP40]. The lysate was centrifuged (2,500 Â g) at 4jC for 10 min, and RNA was extracted in 0.8 mL phenol and 0.4 mL urea buffer [7 mol/L urea, 350 mmol/L NaCl, 10 mmol/L Tris (pH 7.4), 100 mmol/L EDTA (pH 8.0), 1% SDS]. The aqueous layer was extracted by 0.8 mL phenol, followed by 0.6 mL chloroform. RNA was precipitated in 100% ethanol at 80jC for at least 24 h and reconstituted in nuclease-free water. Resuspended RNA was further purified using the RNeasy cleanup kit, and DNase digestion was carried out on the column (Qiagen, Inc.) according to the manufacturer's instructions.
Real-time reverse transcription -PCR. Purified RNA (1 Ag) was reverse-transcribed by Superscript II enzyme (Invitrogen) and random hexamers. cDNA was cleaned-up using the Minelute PCR kit (Qiagen). cDNA (100-400 ng) was combined with TaqMan PCR Master Mix (Applied Biosystems) and run on an ABI PRISM 7000 Sequence Detection System using Irx5 and 18S rRNA (endogenous control) specific primers and MGB probes (Applied Biosystems) as previously described (35) . A standard curve was run to determine efficiency of primer/probe binding. All reactions were carried out in triplicate. RNA expression was quantified by the comparative y-y C t method (Applied Biosystem's User Bulletin 2).
Cell proliferation. LNCaP cells (100,000 per well in six-well plates) were treated with indicated concentrations of 1,25(OH) 2 D 3 24 h after plating. Cells were harvested by trypsinization 96 h after treatment and resuspended in media containing 0.4% trypan blue (Invitrogen). Live cells were counted under a microscope using a hemocytometer (Hausser Scientific).
Small interference RNA. Small interference (siRNA) molecules aligned with Irx5 mRNA were synthesized by Dharmacon as desalted duplexes with the following sense sequences: si1 5 ¶-GCC UCA GCG ACU CGG AUU UdT dT-3 ¶, si2 5 ¶-GAG AGA GAC AGA GAG AGA AdT dT-3 ¶, si3 5 ¶-CAU CGU CGG ACA AGG UCA AdT dT-3 ¶. Cells were plated in RPMI 1640 containing 10% fetal bovine serum and transfected 36 h later with 133 Amol/L siRNA using Oligofectamine reagent (Invitrogen) in serum-free media according to the manufacturer's protocol. 10% Fetal bovine serum was added to transfected cells 4 h after transfection. Effects of Irx5 knockdown were normalized to CY3-labeled luciferase GL2 duplex (control; Dharmacon) with target sequence 5 ¶-CGT ACG CGG AAT ACT TCG A-3 ¶.
Western blot analysis. LNCaP cells were washed twice in PBS and lysed in radioimmunoprecipitation assay buffer (1ÂPBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.01% phenylmethylsulfonyl fluoride, 1Â complete protease inhibitor cocktail; Roche). The lysate was incubated on ice for 1 h. Growth media containing dead cells was aspired and centrifuged for 5 min in chilled tabletop centrifuge at 4,000 Â g. Pelleted cells were washed with PBS and combined with radioimmunoprecipitation assay buffer lysate. Cellular debris was pelleted in chilled microcentrifuge at 10,000 Â g for 30 min, and the supernatant was isolated. Protein concentrations were measured using Bradford reagent (Bio-Rad). Protein samples were resolved on a 10% NuPAGE precast gel (Invitrogen), transferred to a polyvinylidene difluoride membrane (Amersham), and probed with polyclonal antibody anti -poly (ADP-ribose) polymerase (PARP) p85 fragment (Promega) or polyclonal anti-p21 antibody (Santa Cruz). Loading control was accessed using monoclonal anti -h-tubulin antibody (Sigma), polyclonal anti-actin antibody, or anti -glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz). A horseradish peroxidaseconjugated secondary antibody (Santa Cruz) was used to visualize proteins with standard luminol reagents (Perkin-Elmer Life Sciences, Inc.).
Hoechst staining. Trypsinized and floating cells were washed in PBS, pelleted, and resuspended in 3% paraformaldehyde/PBS solution (Sigma). To visualize apoptotic cells, cells were subsequently stained with Hoechst 33258 pentahydrate (Molecular Probes) and counted under a microscope with UV light source (excitation, 350-365 nmol/L). An average of 300 to 500 cells was counted per sample. Apoptotic cells with at least three nuclear fragments were scored and represented as a total of counted cells.
Overexpression. Statistical analysis. Means were compared using Student's t test or ANOVA when more than two samples were analyzed simultaneously. (34) . After RNA extraction, the Affymetrix U133A chip was used to compare gene expression profiles in 10 prostate cancer specimens (samples confirmed to consist predominantly of adenocarcinoma by frozen section examined by a pathologist) collected after 4 weeks of high-dose 1,25(OH) 2 D 3 or placebo therapy. The results showed that the homeobox gene Irx5 is downregulated in 1,25(OH) 2 D 3 -treated tumors relative to controls (raw P = 0.0000008, FDR = 33%; data not shown).
Subsequently, the effect of 1,25(OH) 2 D 3 therapy on downregulation of Irx5 expression was confirmed in the same human specimens using real-time reverse transcription -PCR (RT-PCR). As shown in Fig. 1A , Irx5 mRNA levels, measured by real-time RT-PCR, are reduced 3-fold in 1,25(OH) 2 D 3 -treated patients compared with placebo-treated controls.
To further validate this target and develop a model system for laboratory investigation, the effect of 1,25(OH) 2 Fig. 1D ). Fig. 2A , was associated with a 50% reduction in LNCaP cell numbers (P < 0.001, t test) at 96 hours. A time course of the effect of si2 on LNCaP cell survival shows that cell numbers were reduced by f60% at 120 hours compared with control siRNA-transfected cells (Fig. 2B) .
Down-regulation of
All siRNA oligonucleotides were searched against the human genome, and no identical sequences were found. However, considering the possibility that Irx5 RNA interference oligonucleotides may interact with a similar mRNA sequence in another gene, a third Irx5 siRNA (si3) targeting the open reading frame of Irx5 was tested to ensure that the effects observed were specific to Irx5. Figure 2C shows that this siRNA construct (si3) also significantly reduced LNCaP cell numbers at 96 hours compared with controls. When compared with the results with 1,25(OH) 2 D 3 , Irx5 knockdown had a similar effect on LNCaP cell survival at 96 hours as 10 nmol/L 1,25(OH) 2 D 3 (Fig. 1D) . These data suggest that Irx5 may serve as an important mediator for 1,25(OH) 2 D 3 sensitivity in LNCaP cells. Because specific Irx5 down-regulation was found to have substantial inhibitory effects on prostate cancer cells, Irx5 may function as a tumor promoter in these cells. In addition, MCF-7 breast (Fig. 3A) and HCT 116 colon cancer cells (Fig. 3B ) transfected with Irx5 siRNA (si2) showed significantly reduced cell numbers at 96 hours compared with transfection with a siRNA control, indicating that Irx5 expression may be important in the regulation of a number of different tumor cells.
Down-regulation of Irx5 by RNA interference induces apoptosis of LNCaP cells. To examine the cellular mechanism of cell number reduction by Irx5 knockdown, we determined if apoptosis is induced by Irx5 gene targeting. Log-phase cultures were treated with siRNA Irx5 (si2) or siRNA control and assessed for apoptosis by fluorescent microscopy. Figure 4A shows the difference in morphology between nonapoptotic control cells and apoptotic Irx5 siRNA-transfected cells displaying several apoptotic bodies. Irx5 knockdown resulted in apoptosis of f15% of the cells at 120 hours compared with controls (Fig. 4B) . The induction of apoptosis by Irx5 siRNA was also shown by detection of the PARP cleavage product, a well-known marker of apoptosis ( Fig. 4C; ref. 36 ). These data indicate that Irx5 may use apoptosis as a primary means of regulating cell survival.
Decreased cell viability induced by Irx5 down-regulation is partially dependent upon p53 gene expression. Currently a role of Irx5 or other Irx family members in signaling apoptosis has not been elucidated, and little is known about the mechanisms LNCaP cells were transfected with either control (GL2) siRNA or Irx5 -specific siRNA (si1, si2, or si3), and cells were counted using a hemocytometer. A, LNCaP cells were counted at 96 h after transfection with Irx5 si1, si2, or control siRNA.
Inhibition was statistically significant for si2 (P < 0.001for si2, t test). B, LNCaP cell numbers at indicated time points after transfection with Irx5 si2 or control siRNA.
The difference between control and si2 is statistically significant (P < 0.0002, t test) at 96 and 120 h. C, LNCaP cell viability 96 h after transfection with Irx5 si2, si3, or control siRNA.The difference between both si2 and si3 and control is statistically significant (P < 0.00001, t test). Results are expressed as mean percentage of control siRNA-transfected cells. Columns, mean of three independent experiments; bars, SD. of apoptotic signaling by other homeobox genes. To study the effect of p53 on Irx5-mediated cell death, we used LNCaP cells that stably overexpress a dominant-negative p53 isoform (LNCaP-248, p53 DN). When Irx5 was inhibited by siRNA interference in cells expressing mutant p53 proteins, PARP cleavage was decreased and delayed compared with LNCaP cells with empty vector controls (LNCaP-EV) that only have endogenous wild-type p53, indicating that the mechanism by which Irx5 knockdown signals cell death is partially p53 dependent (Fig. 5A) . Also, the usual reduction in cell numbers induced by Irx5 down-regulation is partially abrogated in cells expressing mutant p53 proteins compared with LNCaP cells expressing p53 wild-type proteins ( Fig. 5B; P < 0.05, t test) . Furthermore, the wild-type endogenous p53 protein expression is increased (especially at 24 hours posttransfection) as a result of Irx5 knockdown by siRNA (Fig. 5C) , further supporting the involvement of p53 in the Irx5 signaling pathway. Finally, when both LNCaP-EV and LNCaP-248 were treated with Tricostatin A, an HDAC inhibitor that induces p53-independent growth inhibition, similar inhibitory effects were observed in both cell lines (Fig. 5D) .
Irx5 down-regulation induces more robust apoptosis than treatment with 10 nmol/L 1,25(OH) 2 (Fig. 6A) . The result suggests that targeting Irx5 directly may be a more effective strategy to induce apoptosis than treatment with 1,25(OH) 2 D 3 (Fig. 6A) . DNA staining (Hoechst) of 1,25(OH) 2 D 3 -treated cells (10 or 100 nmol/L) also suggests that 1,25(OH) 2 D 3 is less efficient at inducing apoptosis than Irx5 down-regulation (Fig. 6B) . Targeting Irx5 directly may be a more specific way to induce apoptosis and may prevent possible cross-talk from the induction of multiple pathways by vitamin D.
Irx5 down-regulation increases p21 protein expression and induces G 2 -M arrest in LNCaP cells. In view of the welldescribed effects of vitamin D receptor ligands on cell cycle progression, we sought to examine the effect of Irx5 downregulation on cell cycle progression and p21 expression. In Fig. 4 . Down-regulation of Irx5 by siRNA induces apoptosis. Log-phase LNCaP cultures were transfected with Irx5 (si2) or control siRNA at the indicated time points and stained with bis-benzimide (Hoechst). A, the difference in nuclear morphology between nonapopoptic (left) and apoptotic (right) cells was assessed by fluorescent microscopy in control and Irx5 siRNA-treated cells. B, Irx5 and control siRNA-transfected cells were harvested at the indicated time points and stained with bis-benzimide. The difference is statistically significant at 72, 96 (P < 0.02), and 120 h (P = 0.001, t test). Cells with at least three nuclear fragments were scored as apoptotic. Points, mean of triplicate experiments; bars, SD. C, knockdown of Irx5 induces PARP cleavage. LNCaP cells were transfected with Irx5 (si2 or si3) or control siRNA as indicated, and induction of apoptosis was shown by detection of the PARP p85 cleavage product by Western blots. addition to apoptosis, down-regulation of Irx5 by siRNA caused an increase in the cyclin-dependent kinase inhibitor p21 protein levels, indicating that Irx5 may also regulate cell cycle progression (Fig. 7A) . Interestingly, 1,25(OH) 2 D 3 has been shown to increase p21 protein expression in LNCaP cells. The observed increase in p21 protein levels was not preceded by an increase in p21 mRNA as measured by real-time RT-PCR (data not shown), suggesting that Irx5 may be involved in regulating p21 protein stability rather than gene expression. To examine more directly the effects of Irx5 on cell cycle regulation, we analyzed the cells by flow cytometry after their transfection with Irx5 si2 or control siRNA. Figure 7B is a representation of the flow data in triplicate. Irx5 knockdown resulted in a significant accumulation of cells in G 2 -M, both at 48 and 72 hours, confirming that Irx5 knockdown does indeed affect cell cycle progression and indicating that this may be through the regulation of p21 expression. Interestingly, the increase in p21 protein expression observed after Irx5 knockdown is not affected by the absence of functional p53 protein (Fig. 7C ) and therefore is not p53 dependent.
Overexpression of Irx5 decreases p21 and p53. To determine the effects of Irx5 overexpression, LNCaP cells were transiently transfected with an Irx5 overexpression vector containing the Irx5 open reading frame or empty vector control. Irx5 overexpression reduced both p21 and p53 protein levels at the indicated time points in LNCaP cells (Fig. 8A and B) . This provides further evidence of a role of Irx5 in cell cycle regulation.
Discussion
To our knowledge, this is the first report to show that Irx genes are involved in the regulation of apoptosis and cell cycle arrest in human prostate cancer cells. However, recently, it has been shown that an antisense oligodeoxynucleotide capable of simultaneously inducing the loss of Irx1-3 and Irx5 expression in developing lung explants dramatically increased apoptosis of the mesenchymal cells while decreasing cell proliferation (37).
Knockdown of Irx5 leads to an increase in p53 protein expression. We were not able to detect specific phosphorylated/ activated species of p53 in our parental LNCaP protein extracts but did observe phosphorylation of two specific serines in our LNCaP 248 cells, which express high levels of mutant p53 proteins. In the p53 mutant cells, phosphorylation of Ser 15 , which is thought to be involved in p53 ubiquitination/ degradation, was increased by Irx5 knockdown, whereas phosphorylation of Ser 392 , which is involved in p53-induced transcriptional activation, was increased after transfection with Irx5 si2 (data not shown). LNCaP cells expressing mutant p53 proteins also were partially resistant to the growth inhibitory effects of Irx5 knockdown, and PARP cleavage in these cells was delayed and reduced compared with p53 wild-type controls. However, PARP cleavage was increased in the p53 mutant cells after Irx5 knockdown, indicating that at least in part PARP cleavage is p53 independent. p21 protein expression in both p53 wild-type and dominantnegative mutant cells was similarly increased by the knockdown of Irx5, suggesting that the effect of Irx5 on p21 is p53 independent as well. Multiple studies have shown that p21 is induced by both p53-dependent and p53-independent mechanisms. A number of transcription factors, including Sp1, Sp3, MyoD, STAT proteins, and CAAT/enhancer binding proteins activate p21 transcription via p53-independent pathways (38) , and recently, it has been suggested that p21, in addition to inhibiting the cell cycle, also plays a role in regulating cell death (39) . Most of this evidence indicates that p21 protects cells against apoptosis, but a number of reports have shown p21 to be proapoptotic in certain models, and studies in p21-deficient mice suggest that p21 is involved in tumor suppression (40) . We found that p21 protein expression is up-regulated by Irx5 knockdown while p21 mRNA remains unchanged, suggesting the regulation of p21 by posttranscriptional modifications or reduced ubiquitination. p21 expression has previously been found to be regulated by both ubiquitin-dependent and ubiquitin-independent degradation (41 -43) .
Although the cyclin-dependent kinase inhibitor p21 has recently been shown to be involved in the regulation of apoptosis, cell senescence, transcription of several genes, and genome stability (44), p21 is best known for its role in inhibiting the cell cycle. p21 causes cell cycle arrest mainly by inhibiting several of the cyclin/cyclin-dependent kinase complexes, which in turn regulate progression through the cell cycle by reducing phosphorylation of the Rb protein/ inactivating members of the retinoblastoma family (38) . Depending on the cell type and experimental conditions, ectopic expression of p21 leads to G 1 -phase, G 2 -phase, or S-phase arrest (45, 46) . We have shown here that an increase in p21 protein expression induced by a reduction in Irx5 accompanies the G 2 -M cell cycle arrest, indicating that p21 may be responsible for this arrest.
Irx5 has not previously been linked to the effects of vitamin D, but in primary cultures of embryonic quail cardiomyocytes, a complex composed of the Irx4 protein, vitamin D receptor and retinoic X receptor a binds the vitamin D response element in the slow myosin heavy chain 3 gene to repress transcription.
The slow MyHC3 gene is one of the earliest atrial chamberspecific genes expressed during cardiogenesis (23) . This suggests that Iroquois proteins may play a role in vitamin D receptor signaling.
Misexpression of many homeobox genes has been detected in a number of cancers. An elegant study by Gidekel et al. showed that the aberrant expression of the homeobox gene Oct-4 increases the tumorigenic potential of embryonic stem cells and is required for maintenance of the malignant phenotype (47) . Homeobox genes also seem to be involved in cell differentiation. Xiro1 (an Iro gene identified in Xenopus) represses the orthologue of mammalian Gadd45g, which antagonizes neuronal differentiation in Xenopus early development (48) . Recently, Irx5 expression was identified in postnatal bipolar interneurons during retinal development and may play a role in the differentiation of these cells (49) . Homeobox genes also seem to play a role in regulating apoptosis, angiogenesis, and metastasis; however, very little is known about the specific signaling pathways involved (31, 32) . In numerous embryonic tissue types, Iroquois gene expression is regulated spatially and temporally by a number of different signaling pathways, including Sonic Hedgehog, Wingless, Notch, epidermal growth factor receptor, and Hox signaling. Interestingly, these pathways have all been implicated in tumorigenesis.
In the present study, we have shown that the homeobox protein Irx5 is down-regulated by 1,25(OH) 2 D 3 in human prostate cancer tissue, in the prostate cancer cell line LNCaP, and in MCF-7 breast cancer cells. Irx5 knockdown in LNCaP cells leads to a reduction in cell number, increased p21 and p53 protein expression, G 2 -M cell cycle arrest, and increased apoptosis and also results in reduced cell survival in the colon cancer cell line HCT 116 and in MCF-7 cells. Conversely, forced expression of Irx5 increases p21 and p53 expression. These data indicate that Irx5 may be a promising new therapeutic target in cancer treatment.
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